We are pleased to announce that Dnyanesh Talpade, our newest CEO-In-Residence, has accepted the role of CEO for Ebisyn Medical. Ebisyn Medical is a spin-out start-up company centered around a medical device for early detection of Autism symptoms. The eye gaze system for autism detection is a head-free, remote system that detects a subject’s pupil and tracks the eye gaze point on a computer screen. The eye gaze system uses alternate flashing of two light sources to generate two differentially illuminated images – a bright pupil image and a dark pupil image. These images are subtracted from each other for accurate pupil detection and gaze determination. The images are simple, resulting in reduced processing load, and faster system speed. The system and software have been specialized for screening infants for autism, and only requires a one-point calibration measurement. No other system on the market has this simple, rapid one point of gaze format. We are confident that Dnyanesh Talpade will provide the skills and expertise necessary to foster Enisyn into success.
Dnyanesh Talpade is the Founding Partner of Verona Ventures Investments LLC and brings over twenty years of medical device experience to IPShakti. Most recently he was CEO of Entubis Medical, a privately held medical technology company developing minimally invasive treatments to middle ear disorders. He was previously the Regional Head of Research and Development for North America at Becton, Dickinson and Company’s Pharmaceutical Systems division, developing solutions to the parenteral drug delivery markets including prefilled syringes and self administration devices. Prior to that, he led the R&D organization of C.R. Bard’s Biopsy Division and was on the leadership team for Bard Biopsy Systems and Bard Peripheral Vascular. He was responsible for successful launches of multiple new products in the mechanical and electromechanical breast biopsy space. Mr. Talpade actively participated in identification, due diligence and negotiations of acquisition targets to build the organization. Before this, he steadily rose through the ranks at Boston Scientific Corporation’s Cardiology division managing emerging technologies, developing markets and being responsible for numerous successful concepts through commercial launches of minimally invasive products. Mr. Talpade is currently named as an inventor on 13 issued US patents. He received his Master of Business Administration in Strategy and Finance from the Carlson School of Management at the University of Minnesota, his Master of Science in Biomedical Engineering from the University of Texas at Arlington and the University of Texas Southwestern Medical Center and his Bachelor of Engineering in Electronics and Communications Engineering from the Manipal Institute of Technology.